Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials

Purwar, Roli; Ranjan, Rakesh; Pal, Manjusha; Upadhyay, Satyanshu K.; Kumar, Tarun; Pandey, Manoj

doi:10.1186/s12957-023-03027-4

Table 1 Baseline characteristics of the included studies and Jadad score

From: Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials

Author name and year	Trial name	Design	Settings	Phase	Total number of patients	Case	Control	BRCAm		HRD, BRCAm		HRD, BRCA uk		HRD, BRCAwt		HRP		HRDuk, BRCAwt		PROC		JADADE SCORE R + B + D
Author name and year	Trial name	Design	Settings	Phase	Total number of patients	Case	Control	Case	Control	Case	Control	Case	Control	Case	Control	Case	Control	Case	Control	Case	Control	JADADE SCORE R + B + D
Penson et al. 2020 [19]	SOLO 3	Olaparib 600 mg vs single-agent chemotherapy	Treatment in recurrent PSOC	3	266	178	88	178	88													2 + 1 + 1
Pujade et al. 2017 [21]	SOLO 2	Olaparib 300 mg vs Placebo	Maintenance in recurrent PSOC	3	295	196	99	196	99													2 + 2 + 1
Moore et al. 2018 [7]	SOLO 1	Olaparib 600 mg vs placebo	Maintenance in primary advanced PSOC	3	391	260	131	260	131													2 + 2 + 1
Coleman et al. 2019 [6]	VELIA	PC + veliparib 300 mg or PC + veliparib 300 mg + veliparib maintainace vs PC + placebo + placebo maintainence	Treatment followed by maintenance in primary advanced PSOC	3	1140	383/382	375	108	92			214	207	106	115	125	124	245	254			1 + 2 + 1
Wu et al. 2021 [25]	NORA	Niraparib 300 mg vs placebo	Maintenance in recurrent PSOC		265	177	88	177	88													2 + 2 + 1
González-Martín et al. 2019 [11]	PRIMA	Niraparib 300 mg or 200 mg vs placebo	Maintenance in primary advanced PSOC	3	733	487	246			152	71			95	55	169	80					1 + 2 + 1
Coleman et al. 2017 [10]	ARIEL 3	Rucaparib 1200 mg vs placebo	Maintenance in recurrent PSOC	3	564	375	189	130	66			236	118	106	52	107	54	32	17			2 + 2 + 1
Vanderstichele et al. 2022 [23]	CLIO	Olaparib 600 mg vs physicians choice CT	Treatment in recurrent PSOC and PROC	3	160	107	53	18	4									89	49	67	33	1 + 0 + 1
Kristeleit et al. 2022 [13]	ARIEL 4	Rucaparib 1200 mg vs CT	Treatment in recurrent PSOC and PROC	3	349	233	116	233	116											110	51	2 + 0 + 1
Colombo et al. 2022 [24]	BAROCCO	Olaparib + cediranib(inttermittent/continous) vs paclitaxel in PROC	Treatment in recurrent PROC	2	123	82	41															2 + 0 + 1
Oza et al. 2015 [18]		Olaparib + pc f/b olaparib vs pc f/b placebo	Treatment f/b Maintenance in recurrent PSOC	2	162	81	81	20	21													2 + 0 + 1
Lederman et al. 2012 [14]		Olaparib 800 mg vs placebo	Maintenance in recurrent PSOC	2	265	136	129	74	62									57	61			2 + 2 + 1
Kaye et al. 2012 [12]		Olaparib 400 mg or 800 mg vs pegylated liposomal doxorubicin	Maintenance in recurrent PSOC	2	97	64	33															2 + 0 + 1

PC Paclitaxel + carboplatin, PROC platinum-resistant ovarian cancer, PSOC platinum-sensitive ovarian cancer, BRCAm BRCA mutated, BRCA wt BRCA wild type, HRD homologous recombination-deficient, HRP homologous recombination proficient, BRCAuk BRCA status unknown, HRDuk HRD status unknown, R + B + D randomization + blinding + details of drop outs

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us